The seroepidemiology of Bordetella pertussis in Israel-Estimate of incidence of infection

Vaccine

Volumn 28, Issue 19, 2010, Pages 3285-3290

  Rendi Wagner, Pamela ^a   Tobias, Joshua ^b   Moerman, Larisa ^c   Goren, Sophy ^a   Bassal, Ravit ^c   Green, Manfred ^c,d   Cohen, Dani ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c MINISTRY OF HEALTH   (Israel)

^d UNIVERSITY OF HAIFA   (Israel)

Author keywords

IgG pertussis toxin; Incidence of infection; Pertussis (whooping cough); Seroprevalence; Vaccination

Indexed keywords

IMMUNOGLOBULIN G; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; BORDETELLA PERTUSSIS; CHILD; CROSS-SECTIONAL STUDY; FEMALE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; INCIDENCE; ISRAEL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PERTUSSIS; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROEPIDEMIOLOGY; SEROLOGY; VACCINATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, BACTERIAL; ANTITOXINS; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; INFANT; ISRAEL; MALE; MIDDLE AGED; PERTUSSIS TOXIN; PERTUSSIS VACCINE; SEROEPIDEMIOLOGIC STUDIES; VACCINATION; WHOOPING COUGH; YOUNG ADULT;

EID: 77950471484     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.104     Document Type: Article

References (30)

1. Cherry J.D. The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United Sates: a comparative study. Curr Probl Pediatr 14 (1984) 1-78
2. Celentano L.P., Massari M., Paramatti D., Salmaso S., Tozzi A.E., and EUVAC-NET Group. Resurgence of pertussis in Europe. Pediatr Infect Dis J 24 9 (2005) 761-765
3. Tanaka M., Vitek C.R., Pascual F.B., Bisgard K.M., Tate J.E., and Murphy T.V. Trends in pertussis among infants in the United States, 1980-1999. J Am Med Assoc 290 (2003) 2968-2975
4. Baron S., Njamkepo E., Grimprel E., Begue P., Desenclos J.C., Drucker J., et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J 17 (1998) 412-418
5. De Melker H.E., Schellekens J.F.P., Neppelenbroek S.E., Mooi F.R., Rumke H.C., and Conyn-van Spaendonck M.A.E. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis 6 4 (2000) 348-357
6. Moerman L., Leventhal A., Slater P.E., Anis E., Yishai R., and Marva E. The re emergence of pertussis in Israel. Isr Med Assoc J 8 (2006) 308-311
7. Rendi-Wagner P., Kundi M., Mikolasek A., Vecsei A., Fruhwirth M., and Kollaritsch H. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine. Vaccine 24 (2006) 5960-5965
8. Ntezayabo B., De Serres G., and Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 22 (2003) 22-27
9. de Melker H.E., Versteegh F.G., Conyn-Van Spaendonck M.A., Elvers L.H., Berbers G.A., van Der Zee A., et al. Specificity and sensitivity of high levels of immunoglobuline G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 38 (2000) 800-806
10. Giammanco A., Nardone A., Pebody R., Kafatos G., Andrews N., Chiarini A., et al. European Sero-Epidemiology Network 2: standardisation of immunoassay results for pertussis requires homogeneity in the antigenic preparations. Vaccine 26 35 (2008) 4486-4493
11. Giammanco A., Chiarini A., Maple P.A., Andrews N., Pebody R., Gay N., et al. European Sero-Epidemiology Network: standardisation of the assay results for pertussis. Vaccine 22 1 (2003) 112-120
12. de Melker H.E., Versteegh F.G., Schellekens J.F., Teunis P.F., and Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect 53 2 (2006) 106-113
13. Teunis P.F., van der Heijden O.G., de Melker H.E., Schellekens J.F., Versteegh F.G., and Kretzschmar M.E. Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis. Epidemiol Infect 129 3 (2002) 479-489
14. Ministry of Health, State of Israel. Notifiable Infectious Diseases in Israel, 54 years of Surveillance, 1951 to 2004. Israel Center for Disease Control, Publication No. 245; May 2006.
15. Pebody R.G., Gay N.J., Giammanco A., Baron S., Schellekens J., Tischer A., et al. The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiol Infect 133 1 (2005) 159-171
16. Nagel J., de Graaf S., and Schiif-Evers D. Improved serodiagnosis of whooping cough of IgG anti-LFP antibody levels. Dev Biol Stand 61 (1985) 325-330
17. Cagney M., McIntyre P.B., Heron L., Giammanco A., and MacIntyre C.R. The relationship between pertussis symptomatology, incidence and serology in adolescents. Vaccine 26 (2008) 5547-5553
18. Gordon M., Davies H.D., and Gold R. Clinical and microbiological features of children presenting with pertussis to a Canadian pediatric hospital during an eleven-year period. Pediatr Infect Dis J 13 (1994) 617-622
19. Wirsing von Konig C.H., Postels-Multani S., Bock H.L., and Schmitt H.J. Pertussis in adults: frequency of transmission after household exposure. Lancet 346 (1995) 1326-1329
20. Thomas M.C., and Lambert H.P. From whom do children catch pertussis?. Br Med J 295 (1987) 751-752
21. Crowcroft N.S., Booy R., Harrison T., Spicer L., Britto J., Mok Q., et al. Severe and unrecognized: pertussis in UK infants. Arch Dis Child 88 (2003) 802-806
22. Quinn H.E., McIntyre P.B., Backhouse J.L., Gidding H.F., Brotherton J., and Gilbert G.L. The utility of seroepidemiology for tracking trends in pertussis infection. Epidemiol Infect 1 (2009) 1-8
23. Klement E., Uliel L., Engel I., Hasin T., Yavzori M., Orr N., et al. An outbreak of pertussis among young Israeli soldiers. Epidemiol Infect 131 3 (2003) 1049-1054
24. Arav-Boger R., Ashkenazi S., Gdalevich M., Cohen D., and Danon Y.L. Seroprevalence of pertussis antibodies among adolescents in Israel. Isr Med Assoc J 2 (2000) 174-177
25. Srugo I., Benilevi D., Madeb R., Shapiro S., Shohat T., Somekh E., et al. Pertussis infection in fully vaccinated children in day-care-centers, Israel. Emerg Infect Dis 6 5 (2000) 526-529
26. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10-year community study. Br Med J 296 (1988) 612-614
27. Qiushui H., Viljanen M.K., Nikkari S., Lyytikainnen R., and Mertsola J. Outcomes of Bordetella pertussis infection in different age groups of an immunized population. J Infect Dis 170 (1994) 873-877
28. Van Boven M., de Melker H.E., Schellekens J.F.P., and Kretzschmar M. Waning immunity and sub-clinical infection in an epidemic model: implications for pertussis in The Netherlands. Math Biosci 164 (2000) 161-182
29. Forsyth K.D., Wirsing von Konig C.H., Tan T., Caro J., and Plotkin S. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 25 14 (2007) 2634-2642
30. Tan T., Halperin S., Cherry J.D., Edwards K., Englund J.A., Glezen P., et al. Pertussis immunization in the Global Pertussis Initiative North American region: recommended strategies and implementation considerations. Pediatr Infect Dis J 24 5 Suppl. (2005) S83-S86